Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ: JUNS) entered into a securities purchase agreement for a registered direct offering of 307,692 shares of common stock, expected to generate approximately $2.0 million in gross proceeds. D. Boral Capital is serving as the exclusive placement agent.
The offering is being made under Jupiter’s effective Form S-3 shelf registration statement (No. 333-295085), declared effective by the SEC on April 24, 2026. Closing is expected on or about August 24, 2026, subject to customary closing conditions. A prospectus supplement describing the terms will be filed with the SEC and made available through the SEC and D. Boral Capital.
Positive
- $2.0 million gross proceeds expected from registered direct offering
- Equity raise of 307,692 common shares under effective Form S-3 shelf
- Exclusive placement agent engagement with D. Boral Capital LLC
Negative
- Issuance of 307,692 new common shares implies shareholder dilution
- Offering closing remains subject to customary closing conditions
News Explained
The issuance is not yet closed; if completed, it would dilute existing ownership, with gross proceeds equal to 78.4 days of latest-quarter operating cash use.
The offering is agreed but not closed: if completed, Jupiter would issue
A registered direct is a negotiated sale to selected investors; in this structure, the placement agent’s fee reduces the company’s net proceeds.
The
The expected
Sources and calculations
- Jupiter Neurosciences registered direct offering release (2026-08-21)
- Dilution definition (2026-07-17)
- Registered direct offering definition (2026-07-17)
- Jupiter Neurosciences second-quarter fundamentals (2026Q2)
- Offering gross vs quarterly operating cash outflow, in days of cash use $2,000,000 / ($2,294,922 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $1,521,874 / ($2,294,922 / 90) = [object Object]
Market Reaction – JUNS
Following this news, JUNS has gained 43.52%, reflecting a significant positive market reaction. Argus tracked a trough of -21.9% from its starting point during tracking. Our momentum scanner has triggered 88 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $7.42. Trading volume is exceptionally heavy at 116.8x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Registered direct offering | Negative | -12.2% | Registered direct offering closed with $2.0 million in gross proceeds |
| May 20 | Registered direct offering | Negative | -35.9% | Registered direct offering priced for $2.0 million in gross proceeds |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-tagged events both had negative 24-hour reactions, averaging -24.06%.
Key Terms
securities purchase agreement financial
registered direct offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
The gross proceeds of the offering are approximately
D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.
The closing of the Offering is expected to occur on or about August 24, 2026, subject to the satisfaction of customary closing conditions.
The shares of common stock are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026.
A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC. Once filed, it will be available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com
Tel: +1 561 406 6154
